 |
|
|
| |
Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Infection and Prior Treatment Experience: An Integrated Phase II/III Analysis
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Fred Poordad1, Stefan Zeuzem2, Armen Asatryan3, Graham R Foster4, Edward Gane5, David L Wyles6, Stanislas Pol7, Maria Buti 8, Paul Kwo9, Tarik Asselah10, Kris Kowdley11, Christophe Hezode12, Kosh Agarwal13, Stanley Wang3, Neddie Zadeikis3, Teresa I Ng3, Tami Pilot-Mati as3, Yang Lei3, Jens Kort3, Chih-Wei Lin3, Federico J Mensa3
1The Texas Liver Insti tute, University of Texas Health, San Antonio, Texas, United States; 2Goethe University Hospital, Frankfurt, Germany; 3AbbVie Inc., North Chicago, Illinois, United States; 4Queen Mary University of London, Barts Health, London, United Kingdom; 5Liver Unit, Auckland City Hospital, Auckland, New Zealand; 6Denver Health Medical Center, Denver, Colorado, United States; 7Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 8Vall d'Hebron University Hospital and CiBERHED del Insti tuto Carlos III, Barcelona, Spain; 9Stanford University Division of Gastroenterology and Hepatology, Palo Alto, California, United States; 10Centre de Recherche sur l'Infl ammati on, Inserm UMR 1149, Universite Paris Diderot, Service d'hepatologie, AP-HP Hopital Beaujon, Clichy, France; 11Swedish Medical Center, Seatt le, Washington, United States; 12Hopital Henri Mondor, Universite Paris-Est, Creteil, France; 13Insti tute of Liver Studies, Kings College Hospital, London, United Kingdom
|
| |
|
|
|
|
|
